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Levothyroxine effects on depressive symptoms and limbic
glucose metabolism in bipolar disorder: a randomized,
placebo-controlled positron emission tomography study
M Bauer1,2, S Berman2, T Stamm3, M Plotkin4, M Adli3, M Pilhatsch1, ED London2, GS Hellemann5, PC Whybrow2 and F Schlagenhauf3
Adding supraphysiologic doses of levothyroxine (L-T4) to standard treatment for bipolar depression shows promise, but the
mechanisms underlying clinical improvement are unknown. In a previous pilot study, L-T4 treatment reduced depression scores
and activity within the anterior limbic network. Here we extended this work in a randomized, double-blind, placebo-controlled
study of patients with bipolar depression. Cerebral glucose metabolism was assessed with positron emission tomography and
[F-18]fluorodeoxyglucose before and after 6 weeks of treatment with L-T4 (n= 15) or placebo (n= 10) in 12 volumes of interest
(VOIs): the bilateral thalamus, amygdala, hippocampus, dorsal striatum and ventral striatum, and midline cerebellar vermis and
subgenual cingulate cortex. Radioactivity in the VOIs, normalized to whole-brain radioactivity was taken as a surrogate index of
glucose metabolism, and markers of thyroid function were assayed. Changes in brain activity and their association with clinical
response were assessed using statistical parametric mapping. Adjunctive L-T4 treatment produced a significant decline in
depression scores during the 6-week treatment. In patients treated with L-T4, we found a significant decrease in regional
activity at Po0.05 after Bonferroni correction in the left thalamus, right amygdala, right hippocampus, left ventral striatum and the
right dorsal striatum. Decreases in the left thalamus, left dorsal striatum and the subgenual cingulate were correlated with a
reduction in depression scores (Po0.05 after Bonferroni correction). Placebo treatment was associated with a significant decrease
in activity only in the right amygdala, and no region had a change in activity that was correlated with change in depression
scores. The groups differed significantly in the relationship between the changes in depression scores and in activity in the
thalamus bilaterally and the left ventral striatum. The findings provide evidence that administration of supraphysiologic thyroid
hormone improves depressive symptoms in patients with bipolar disorder by modulating function in components of the anterior
limbic network.
Molecular Psychiatry (2016) 21, 229–236; doi:10.1038/mp.2014.186; published online 20 January 2015
INTRODUCTION
For most patients with bipolar disorder, depression is the most
difficult phase of the illness to treat.1 The overall evidence from
treatment trials in bipolar depression is sparse, and the role of
antidepressants and their efficacy remains controversial.2–5
Adjunctive treatment with thyroid hormone is one approach for
treatment-refractory bipolar disorders. Such use of levothyroxine
(L-T4) at supraphysiologic doses has offered promise in several
open-label studies, including rapid cycling,6 prophylaxis-resistant
bipolar patients7 and for patients with refractory uni- or bipolar
depression.8
The hypothesis driving these studies was that increasing the
availability of thyroid hormones to the brain changes the
phenotypic expression of the disorder and is associated with
improvement of mood and cognition.9 Supporting this hypothesis
are observations that suboptimal thyroid hormone levels have
been associated with an unfavorable acute and longer-term
treatment outcome in patients with bipolar disorders.10–12 In a
pilot study of women with bipolar depression, the decline in
depression in those treated with L-T4 was significantly associated
with changes in regional cerebral glucose metabolism in limbic
and subcortical circuits, brain areas that are integral to the
regulation of affect and cognition.13 Specifically, treatment with
supraphysiologic doses of L-T4 decreased relative activity in the
subgenual cingulate cortex, thalamus, amygdala, hippocampus,
dorsal and ventral striatum, and the cerebellar vermis. Further-
more, it was demonstrated that the decrease in relative activity in
the latter brain regions was significantly correlated with reduction
in depression scores.13
The aims of this randomized, placebo-controlled double-blind
study of euthyroid bipolar depressed patients were to test the
hypotheses that treatment with adjunctive supraphysiologic doses
of L-T4 would be more effective than placebo treatment
(reduction in depressive symptoms), and that clinical improve-
ment would be more associated with reduction in relative regional
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cerebral metabolism in pre-defined limbic and subcortical regions,
as compared with the corresponding changes in placebo-treated
patients. A secondary hypothesis was that there would be a
greater reduction in relative brain activity in these pre-defined
regions after L-T4 as compared with placebo treatment.
MATERIALS AND METHODS
Study design
This 6-week, double-blind, randomized, placebo-controlled study assessed
the efficacy of L-T4 (300mcg per day, fixed dose) in bipolar depressed
patients who had failed a course of treatment with mood stabilizer and/or
antidepressant medication. The study was part of a larger multisite clinical
trial (registered with ClinicalTrials.gov, identifier: NCT01528839).14 Partici-
pants in the study reported here (n=25; 15 with bipolar disorder type I and
10 with bipolar disorder type II) were recruited from a single site in Berlin,
where positron emission tomography (PET) technology was available.
Image analyses were performed at the Laboratory of Molecular Imaging,
Semel Institute for Neuroscience and Human Behavior, University of
California Los Angeles.
Clinical response was measured by the change in Hamilton Rating Scale
for Depression (HamD17) total score from randomization to completion of
treatment. Brain function was inferred from normalized, decay-corrected
raw counts from the radiotracer [F-18]fluorodeoxyglucose (FDG) as a
surrogate index of glucose metabolism. Relative activity, as used in this
report, refers to this measure.
The study was approved by the local institutional review board (Ethical
Committee at Charité–Universitätsmedizin Berlin) and performed in
accordance with the current amendment of the Declaration of Helsinki
and the International Conference on Harmonization/Good Clinical Practice
guidelines. Written informed consent was obtained from all subjects.
Subjects
Research participants were 18–65 years of age and diagnosed with bipolar
disorder, type I or II, according to the DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, Fourth EditionIV). The patients in this
study had failed to respond to at least 6 weeks of treatment with a mood
stabilizer and/or antidepressant (see below) at standard doses according
to an international guideline.15 They were required at both the
screening and randomization assessments to have an overall score ⩾ 14
on the HamD17,
16 a HamD item 1 (depressed mood) score⩾ 2 and a
Young Mania Rating Scale17 score ⩽ 12. Serum levels of lithium were
required to be within therapeutic ranges (0.5–0.8 mmol l− 1) for at least
2 weeks before enrollment in this study of adjunctive thyroid hormone
treatment.
Patients who met any of the following criteria were excluded: (1) an axis I
disorder other than bipolar disorder, (2) ultra-rapid cycling, defined as ⩾ 12
episodes in the previous year, (3) psychotic features, (4) a diagnosis of
substance dependence or substance use (except for nicotine) over the
previous year, (5) a clinically significant current medical illness, or (6) current
or past thyroid disease or thyroid hormone treatment. Serum thyroid
hormone (free thyroxine (fT4) and free triiodothyronine (fT3)) and thyroid-
stimulating hormone (TSH) levels were required to fall within the normal
reference range of the laboratory (fT4: 0.9–1.9 ng dl− 1; fT3: 2.6–5.1 ng l− 1;
TSH 0.27–4.2 mU l− 1) in order to exclude subthreshold thyroid disease.
Procedures
Following a screening interview, subjects meeting preliminary entry criteria
were invited to participate. After providing written informed consent,
participants received a psychiatric interview supplemented by the
Structured Clinical Interview for DSM-IV Axis I Disorders,18 to confirm the
diagnosis of bipolar disorder, a complete medical and physical examina-
tion, a routine laboratory evaluation (thyroid function tests, blood count,
blood chemistry and urine drug screen), vital signs and a 12-lead
electrocardiogram. Affective symptoms were assessed with the HamD17
and Young Mania Rating Scale. Participants were reassessed 1 week after
the qualifying examination and, on still fulfilling study criteria, were
randomized to receive adjunctive L-T4 (n= 15) or placebo (n= 10) for a
double-blind 6-week period. L-T4 or placebo was administered orally each
day before breakfast. L-T4 was administered at 100mcg per day during
week 1, 200mcg per day during week 2 and 300mcg per day during weeks
3–6. Placebo and active tablet packaging were identical in appearance.
At study entry, patients in both groups were receiving a variety of
psychotropic medications (there were no significant group differences); all 25
patients received at least one mood stabilizer (lithium, carbamazepine,
valproate, lamotrigine or an atypical antipsychotic approved for bipolar
disorder), except for two bipolar II patients who received only one
antidepressant (duloxetine or nortriptyline). Fifteen patients received two
psychotropic medications, seven received three and one patient received four.
The medications in the group that received adjunctive L-T4 treatment were as
follows: buproprione, n=1 (300mg per day); carbamazepine, n=2 (400–
600mg per day); citalopram, n=1 (60mg per day); duloxetine, n=1 (120mg
per day); lamotrigine, n=3 (100–150mg per day); lithium carbonate, n=7
(600–1200mg per day); mirtazapine, n=1 (30mg per day); nortriptyline, n=1
(100mg per day); olanzapine, n=1 (10mg per day); pregabaline, n=1
(500mg per day); risperidone, n=1 (4mg per day); sertraline, n=2 (100–
150mg per day); tranylcypromine, n=1 (20mg per day); venlafaxine, n=2
(150–375mg per day); valproate, n=1 (800mg per day).
The medications in the group that received placebo treatment were as
follows: amisulpride, n= 1 (200mg per day); amitriptyline, n=1 (750mg
per day); carbamazepine, n= 1 (600mg per day); citalopram, n= 1 (40mg
per day); lamotrigine, n= 4 (25–200mg per day); lithium carbonate, n= 4
(200–1200mg per day); mirtazapine, n= 1 (45mg per day); olanzapine,
n= 1 (10mg per day); quetiapine, n= 1 (700mg per day); venlafaxine, n= 2
(225 g per day); valproate, n= 2 (1200–1500mg per day); ziprasidone, n= 1
(80mg per day). There was no change in treatment with any of these
medications in either group 2 weeks prior randomization and throughout
the study.
Zolpidem tartrate (5–10mg per day at bedtime for insomnia) and
lorazepam (1–3mg per day for severe anxiety) were permitted at the
discretion of the study physician during the first 3 weeks, but withheld
within 8 h before any assessment was conducted. No other psychotropic
drug (except the prescribed mood stabilizers and/or antidepressants listed
above) was allowed during the study.
Clinical assessments were conducted at screening, baseline and at the
end of each week in the 6-week treatment period. The measure of
treatment efficacy was the mean change from baseline in HamD17 score.
Adverse events were assessed from spontaneous self-reports. The clinician
asked the subject whether any events, independent of any causal
relationship, had come to attention, using the Thyroid Symptom List, a
specific assessment of thyroid system-related side effects.19 Vital signs,
weight, blood pressure and heart rate were obtained at each assessment.
Electrocardiogram, clinical chemistry, hematology and thyroid function
tests were conducted at screening and treatment weeks 2, 4 and 6.
Magnetic resonance imaging
T1 volumetric structural magnetic resonance imaging scans (3-T, General
Electric, Fairfield, CT, USA) were acquired (spoiled-gradient-recalled
acquisition, 256 × 256 matrix, TE = 3.2 ms, TR = 8ms, angle = 20 °, 2-mm
slice thickness) for co-registration with PET data.
PET imaging
Each subject participated in two PET scanning sessions with FDG.20,21 The
first PET scan was acquired before treatment and the second after 6 weeks
of L-T4 or placebo treatment. Thyroid status and psychiatric ratings were
assessed on the morning of each PET scan. Before each PET measurement,
a catheter was inserted into the antecubital vein for FDG infusion.
Measured blood glucose levels wereo5.6 mmol l− 1 in all cases.
To provide a consistent, affectively neutral cognitive set during
measurement of cerebral activity and to control for variance optimally,
all participants performed an auditory continuous performance task (CPT)
during the radiotracer uptake period. The CPT required discrimination of
rare higher-pitched ‘target’ tones presented within a sequence (inter-tone
interval = 2 s) of more frequent lower-pitched distracting tones. A button
was pressed to signify hearing a target tone.
Subjects performed the CPT while seated. Approximately 15min after
the CPT began, FDG (300MBq) was administered as an intravenous bolus,
followed by a 20-ml saline flush. Thirty minutes after the injection, the CPT
was stopped and the subject was positioned in the scanner gantry. Brain
images were acquired for 30min (six 5-min frames), beginning 50min after
FDG injection.
Static PET brain images of 11 participants (L-T4 n= 7 and placebo n=4)
were acquired with a Siemens ECAT EXACT 47 tomograph (Siemens,
Erlangen, Germany) in 33 planes in three-dimensional mode. Image
reconstruction was performed by filtered back projection using a Hanning
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filter (cut-off 0.4) into a 128× 128 matrix using a zoom of 2. A 10-min
transmission scan using a 68Ge/68Ga rod source was performed for
attenuation correction.
PET images of the other 14 participants (L-T4 n=8 and placebo n=6)
were obtained in three-dimensional mode using a hybrid PET/computed
tomography (CT) system consisting of a multislice CT and a full-ring PET
system (Biograph 16, Siemens). The crystal and block dimensions were
equal to those of the ECAT EXACT detectors, but different detector
materials were used (LSO vs BGO). Intrinsic spatial resolution was
comparable. Pre- and posttreatment PET scans were always acquired with
the same PET scanner for a given patient. An unenhanced CT image
(detector collimation 16× 1.5 mm2, tube current 100mA, tube voltage
120 kV and gantry rotation time 0.8 s) covering the entire head was
performed for attenuation correction. PET emission data were recon-
structed iteratively (OSEM algorithm, 6 iterations, 16 subsets) using a
128× 128 matrix and a zoom of 2.
Data analysis
Differences between the treatment groups in demographic characteristics
and baseline depressive symptoms (HamD17 score) were assessed using
two-tailed Student’s t-test. The hypothesis that depressive symptoms
would improve more after L-T4 than placebo treatment was assessed
through a general linear mixed model. The first analysis modeled the effect
of treatment group (two levels), treatment week (six levels) and their
interaction on the difference scores resulting from subtracting each
subject’s HamD17 score before treatment from the weekly HamD17 scores
during treatment. A second general linear mixed model dropped the
insignificant interaction term. Both models were corrected for age.
Statistical significance for all analyses was set at α=0.05.
Relative activity, reflecting regional glucose metabolism, was compared
between groups and between pre- and posttreatment assessments using
Statistical Parametric Mapping 5 (refs 22,23). Each reconstructed PET image
was co-registered to the corresponding magnetic resonance imaging using
Automated Image Registration.24 The magnetic resonance images were
then used to normalize each subject’s PET data spatially by linear and
nonlinear transformations,22 which warped the images into a standard
coordinate system developed at the Montreal Neurological Institute space
using a study-specific template. Normalized images were then smoothed
with an 8-mm (full width at half maximum) isotropic Gaussian kernel. The
effects of global activity were removed from consideration by proportional
scaling.
On the basis of our previous study of L-T4-treated patients with bipolar
depression,13 we identified 12 volumes of interest (VOI) where we
expected decreases in relative activity after L-T4 treatment, and the
decreases being proportional to improvement in depressive symptoms.
These regions were the thalamus, amygdala, hippocampus, dorsal striatum
and the ventral striatum, measured in each cerebral hemisphere,
subgenual cingulate cortex and the midline cerebellar vermis. The VOIs
were drawn on the structural magnetic resonance template provided in
Statistical Parametric Mapping 5, using MEDx software (Sensor Systems,
Sterling, VA, USA) aided by use of the Talairach and Tournaux atlas25 and
the Human Brain atlas of Duvernoy.26 In combination, the 12 VOIs
constituted 7,349 voxels representing 3.9% of the analyzed whole brain
volume.
We used the Statistical Parametric Mapping 5 small volume correction.
The voxel height threshold for inclusion in statistical parametric maps was
P= 0.05 (uncorrected). A VOI was considered to show a significant effect
only if the probability of obtaining the peak voxel height was Po0.05 after
family-wise error correction for the number of voxels in the VOI.
The first SPM analysis explored the effects of treatment on relative brain
activity. The interaction of treatment group (L-T4 vs placebo) with
treatment session (pre vs post) was evaluated. A second SPM analysis
split each treatment group into responders and non-responders, as
defined by a ⩾ 50% reduction in HamD17 scores after treatment.
A third SPM analysis assessed the degree to which change in relative
activity after treatment was correlated with change in depressed
depressive symptoms (HamD17). In each analysis, age and gender were
modeled as covariates of no interest. Separate contrasts for each group
assessed the differences in relative activity between sessions and the
relationship of these changes to depressive symptoms.
We also noted which effects maintained statistical significance after
applying the Bonferroni correction for the number of regions assessed (five
bilateral regions and two midline volumes). This evidentiary criterion
(0.05/12= 0.0042) is overly conservative, because it assumes tests of the
individual VOIs are independent of one another, which is highly unlikely in
this type of data.
RESULTS
Characteristics of participants
The treatment groups did not differ significantly in gender (female
vs male: L-T4 group n= 8 vs n= 7; placebo group n= 4 vs n= 6),
type of bipolar disorder (type I and II), education, ethnicity or
handedness. HamD17 scores before initiation of treatment (L-T4:
21.7 ± 3.2; placebo: 20.3 ± 6.3) were also equivalent between the
groups as assessed by two-tailed t-test (P= 0.48). However,
participants in the placebo group were older than those in the
L-T4 group (mean 51.8 ± 11.4 years vs 41.3 ± 12.4; t (two-tailed
t= 2.15, P= 0.042). All subsequent analyses were corrected for age.
Treatment outcome
Figure 1 demonstrates the change in HamD17 total score from
randomization over time (6 weeks). General linear mixed model
analysis revealed a significant effect of treatment group
(F1,117 = 9.98, P= 0.002) and treatment week (F5,43 = 4.71,
P= 0.002), but no significant Group ×Week interaction
(F5,43 = 0.93, P= 0.469) or effect of age (F1,79 = 0.31, P= 0.581). A
second general linear mixed model without the interaction term
retained significant effects of treatment group (F1,83 = 6.30,
P= 0.014) and treatment week (F5,44 = 5.47, P= 0.001).
At baseline, all thyroid axis hormone levels (fT4, fT3 and TSH) fell
in the normal range of the laboratory. With L-T4 treatment
(300 mcg per day), thyroid hormone levels increased significantly
(free T4: from 1.11 ± 0.26 to 2.53 ± 0.67 ng dl− 1, Po0.01; free T3:
from 2.80 ± 0.77 to 5.62 ± 1.05 ng dl− 1, Po0.01) and basal TSH
levels decreased significantly (from 2.35 ± 0.94 to 0.02 ± 0.15
mU l− 1; Po0.001), but not with placebo treatment (fT4: from
1.14 ± 0.14 to 1.09 ± 0.19 ng dl− 1; fT3: from 3.39 ± 1.07 to
3.23 ± 0.41 ng dl− 1; and basal TSH: from 1.34 ± 0.61 to 1.53 ± 0.76
mU l− 1). Blood pressure, heart rate and body weight did not
change significantly with either treatment. L-T4 treatment was
well tolerated, with no serious adverse events or side effects that
warranted discontinuation of treatment (data not shown).
0.0
1.0
2.0
3.0
4.0
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7.0
8.0
9.0
10.0
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L-T4
Placebo
Figure 1. Change in Hamilton Rating Scale for Depression (HamD17)
total score from randomization over time (6 weeks). Baseline (week
0) HamD17 score: levothyroxine (L-T4) vs placebo: 21.7 vs 20.3, at
week 6: difference between groups 3.7 (L-T4 vs placebo: 12.6
vs 16.3).
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Change in relative brain metabolism after treatment
Table 1 presents and Figure 2 depicts changes in relative regional
activity of the preselected VOIs from the pre- to posttreatment
session for each treatment group. At the 0.05 α-level, there were
no areas where relative activity increased after treatment in either
group. In patients treated with L-T4, activity decreased after
treatment in a large part of all the preselected regions-of-interest
areas (see Materials and methods) comprising 65% of the total
assessed voxels. There were significant decreases in 10 of the 12
VOIs. Effects in the left thalamus, right amygdala, right hippo-
campus, left ventral striatum and the right dorsal striatum retained
significance after Bonferroni correction for the number of regions
assessed (0.05/12 = 0.0042).
Activity decreased significantly after placebo treatment in 11%
of the assessed voxels, with a significant regional decrease in the
right amygdala. Table 1 and Figure 2 show that parts of some
VOIs, particularly within the right thalamus, appeared to decrease
more in activity after treatment in the L-T4 as compared with the
placebo group, but formal comparisons of group differences
(interaction of PET session with group) attained the α-level in only
6% of assessed voxels and no VOI showed a significant effect after
volume correction.
When the groups were split into responders and non-responders,
there were seven non-responders in the placebo group (mean HamD
decrease=16%, s.d. = 61%) and three responders (mean HamD
decrease=70%, s.d. = 11%). There were eight non-responders in the
L-T4 group (mean HamD decrease=32%, s.d. = 15%) and seven
responders (mean HamD decrease=67%, s.d. = 13%).
The group of three was too small for meaningful statistical
comparison but decreases in relative cerebral activity after
treatments were quantified separately in the other three groups.
In placebo-treated non-responders, 10% of the total assessed
voxels were decreased at Po0.05, but no VOIs retained significant
decreases after volume correction. In L-T4-treated non-responders,
24% of the total voxels decreased at Po0.05, and there were
significant decreases in 4 of 12 VOIs (right amygdala P= 0.016,
right hippocampus P= 0.019, right ventral striatum P= 0.028, right
dorsal striatum P= 0.025). In L-T4-treated responders, 60% of the
voxels decreased at Po0.05, with significant decreases in 8 of 12
VOIs (left thalamus P= 0.001, right thalamus P= 0.007, left
amygdala P= 0.040, right amygdala P= 0.027, right hippocampus
P= 0.040, left ventral striatum P= 0.017, left dorsal striatum
P= 0.014 and cerebellar vermis P= 0.015). Comparing L-T4-treated
responders and non-responders revealed a larger decrease after
treatment in the right thalamus of responders (P= 0.037). There
were no significant differences in metabolic change between non-
responders treated with L-T4 and with placebo.
Symptom-related change in relative brain metabolism after
treatment
To test the primary hypothesis, symptom-related changes in
relative metabolism after treatment were examined. Table 2
presents and Figure 3 depicts VOIs with significant correlation
between changes from the pre- to posttreatment session in
relative regional activity and depressive symptoms assessed with
the HamD17 score. There were no areas with inverse correlation
between change in depressive symptoms and brain activity
change. In the L-T4 group, relative activity decreased as depressive
symptoms improved (for example, positive correlation, as lower
HamD17 scores indicate better mood) in all VOIs (P-values range
from 0.04 too0.0005). In the left thalamus, left dorsal striatum
and the midline subgenual cingulate, the volume-corrected effects
retained significance after Bonferroni correction for the number of
regions assessed. In contrast, change in depressive symptoms
after treatment was not correlated with activity change in any VOI
of the placebo group.T
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Table 2 and Figure 3 suggest that portions of several VOIs
featured more positive correlation of pre- to posttreatment
changes between cerebral activity and depressive symptoms after
L-T4 as compared with placebo treatment. Formal comparisons
were significant in the right thalamus, left thalamus and the left
ventral striatum. Across all VOI voxels, 86% showed Po0.05
correlations in the L-T4 group, but only 2% showed such
correlations in the placebo group; 28% showed correlations that
were larger in the L-T4 than the placebo group.
DISCUSSION
This report is the first randomized, placebo-controlled study in
euthyroid bipolar patients with refractory depression employing
functional brain imaging (FDG–PET) to investigate the effects of
adjunctive L-T4 treatment on regional brain metabolism. The
addition of supraphysiologic doses of L-T4 (300 mcg per day) to an
otherwise stable medication regimen of standard treatments
resulted in a significant decline in depression scores during the 6-
week, double-blind treatment phase. At endpoint (week 6), the
mean HamD score showed a group difference of 3.7 points in
favor of L-T4. Such difference is generally considered to be
clinically meaningful in a short-term treatment trial for major
depression. NICE used a 3.0-point difference in HamD change
scores as a criterion of clinical significance.27
The major biological findings of this study are that L-T4, as
compared with placebo, yields greater clinical improvement in
depression, and that this improvement is strongly correlated with
metabolic changes in areas of the anterior limbic network, with
pronounced effects in the thalamus, striatum and the subgenual
cortex.
Functional brain imaging studies (functional magnetic reso-
nance imaging and PET studies) in depression have provided
evidence for a dysfunctional interaction between frontal lobe
activity and the anterior limbic network, specifically those
interconnected prefrontal, limbic and the striatal regions essential
for emotional homeostasis. These regions include the amygdala,
hippocampus, thalamus, anterior cingulate cortex, orbitofrontal,
ventrolateral and dorsolateral prefrontal cortex, and the
striatum.28 In our previous pilot study of L-T4 in patients with
bipolar depression, which was conducted without a patient
control group,13 it was not possible to differentiate to what
degree changes in depression and related change in brain
metabolic activity were directly in response to L-T4, or occurred
during the natural course of the disorder. This study employing a
placebo–control group differentiates that the changes observed
are in high probability directly related to the adjunctive L-T4.
The most pronounced differences between effects of L-T4
treatment and placebo on brain metabolic activity were the
correlations between clinical and metabolic changes in the
thalamus and the ventral striatum. These changes in the active
L-T4 treatment group appear associated with improved depressive
symptoms.
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Figure 2. Brain areas where relative activity changed after levothyroxine (L-T4) treatment or placebo. Colors superimposed on a gray-scale
structural magnetic resonance template indicate areas where relative metabolism decreased after, as compared with that before treatment (t⩾1.69;
Po0.05), in bipolar disorder patients treated with L-T4 (top row), placebo (center row), or where the decrease was greater in the L-T4 than placebo
group (bottom row). Coordinates are in Montreal Neurological Institute (MNI) space depicted in neurological orientation. PLA, placebo.
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Both the thalamus and ventral striatum have been shown
previously to have abnormally high glucose metabolism in
depressed bipolar patients compared with healthy
controls,13,29,30 which normalized after effective treatment with
L-T4 (ref. 13). A recent review of functional magnetic resonance
imaging investigations of bipolar disorder concluded that the
most consistent abnormalities are activation of the thalamus and
the striatum. It has been hypothesized that excessive activation of
an anterior limbic network may disturb emotional homeostasis
and lead to dysregulation of positive and negative feedback loops
in patients with bipolar disorder.28
One limitation of this study is that it was a necessary subset of a
larger multi-center clinical study, because PET imaging was only
available at the Berlin site. This sample of convenience had the
downside of yielding both unequal sample sizes (15 vs 10) and also
age differences between the groups. The relatively small sample
sizes precluded the quantification of gender effects. Despite these
limitations, for the first time, in this randomized, placebo-controlled
trial of depressed bipolar patients, cerebral metabolic changes are
demonstrated with the use of adjunctive L-T4 treatment.
As in previous studies, the hyperthyroxinemia induced by L-T4
treatment was well tolerated and led to a doubling of fT4 and fT3
levels (with both hormones being slightly above the reference
range), while TSH was suppressed as expected after 6 weeks of
L-T4 treatment. Even in bipolar patients treated with supraphy-
siologic doses of L-T4 for extended periods, no serious effects,
including loss of bone mineral density, were observed in those
previous studies.31,32 The low incidence of adverse effects and
high tolerability reported by patients with bipolar disorders, who
are receiving high-dose thyroid hormone therapy, contrasts with
that typically seen in patients with primary thyroid disease or
healthy controls. As part of an ongoing effort to define tolerability
and safety parameters of supraphysiologic L-T4, we found that
under comparable conditions and doses healthy subjects and
depressed patients respond differently to L-T4: depressed patients
exhibit less elevation in the serum levels of thyroid hormones and
show fewer side effects.33 However, in spite of overall good
tolerability, treatment with supraphysiologic L-T4 requires selec-
tion of adequate patients with a good general physical health
status (especially the absence of severe cardiac disease, arrhyth-
mia in particular) and close (cardiac) monitoring. Given the overall
lack of placebo-controlled data in this area of bipolar depression,
we recommend to use adjunctive L-T4 at a dose of up to 300mcg
per day (depending on individual tolerability) as one option in
difficult-to-treat depressed patients and in non-responders to
standard treatment approaches, respectively.
Although we are only beginning to understand the mechanisms
through which thyroid hormones exert their behavioral effects,
such as those demonstrated in this paper, the brain’s indepen-
dence of peripheral thyroid metabolism suggests that an under-
standing of their therapeutic efficacy requires further central
nervous system investigation. As part of the nuclear superfamily of
ligand-modulated transcription factors, thyroid hormones bind to
nuclear receptors34 where they control, and usually increase, gene
expression influencing a broad array of metabolic processes.35
Genes that are regulated by thyroid hormones are known to
encode for proteins essential for important brain function such as
myelin and neurotrophines. Non-genomic actions after binding to
cytoplasmic thyroid hormone receptors include rapid activation of
the phosphatidylinositol-3-protein kinase pathway and thereby
achievement of vasodilatory and neuroprotective effects.36
Thyroid hormone receptors are widely distributed in the brain
with high concentrations in the cerebral cortex, hippocampus and
the amygdala,37 the latter being limbic structures that are
implicated in the pathogenesis of mood disorders. The regulation
of thyroid hormone homeostasis in the brain underlies a complex
interaction of different mechanisms, some of which overlap with
mechanisms involved in affect regulation.T
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The activity of specific thyroid hormone transporters (for
example, monocarboxylate transporter 8) as clarified in recent
research38, and the carrier transthyretin, are involved in determin-
ing intracellular concentrations of thyroid hormones via mediating
their cellular influx and efflux.39 Deiodinases control regional
effectivity of T3 in concert with other mechanisms,40 that is, the
local distribution of the different nuclear thyroid hormone
receptors TRα and TRβ.37 Deficits in any one, or several, of these
mechanisms may result in reduced bioavailability of thyroid
hormones at cerebral target regions despite normal peripheral
serum levels of thyroid hormones. This condition has been
conceptualized as ‘central hypothyroidism’. Compensation for this
putative ‘central hypothyroidism’ might be one reason why a
proportion of euthyroid depressed patients benefit from admin-
istration of supraphysiologic doses of L-T4. Interestingly, mice
suffering from central hypothyroidism caused by a mutation of
the TRα1 gene,41 showed reduced neuronal density, resulting in
reduced cortical thickness in the hippocampal CA1 region.42
Behaviorally, these mice show increases in surrogate animal
markers for depression and anxiety, as well as an increased startle
response. Both the behavioral and neural density measures
normalized with thyroid hormone administration.41,43
As noted earlier, limbic system structures where thyroid
hormone receptors are prevalent have been implicated in the
pathogenesis of mood disorders. However, the functional path-
ways through which thyroid hormones modulate such depressive
symptoms are poorly understood. Interactions of the thyroid and
neurotransmitter systems, primarily norepinephrine and serotonin,
which are generally believed to have a major role in the regulation
of mood and behavior, may contribute to the mechanism of
action in the developing and mature brain.33,44 In particular, there
is robust evidence from animal research that thyroid hormones
have a modulatory effect leading to an increase in serotonergic
neurotransmission.33 Thyroid hormones also interact with other
neurotransmitter systems involved in mood regulation, including
dopamine postreceptor and signal-transducing processes, as well
as gene regulatory mechanisms.45
Further research is clearly warranted. Despite the clinical
evidence of a close relationship between low thyroid status and
behavioral disturbance, known for more than 100 years, metabolic
effects of thyroid hormones in the adult mammalian brain have
rarely been investigated in vivo.46 In part, this lack of curiosity may
be traced to reports in the 1950s and 1960s, which suggested that
oxygen consumption in the mature human brain did not change
with thyroid status. However, the absence of a technology capable
of direct in vivo measurement of brain thyroid metabolism is
also responsible. Such definitive technology still does not exist.
The evaluation of cerebral blood flow and metabolism by
functional brain imaging techniques, employing selective radi-
oligand binding to receptors of interest in the brain, however,
offers a starting point. This study demonstrates that further
metabolic study of the adjunctive use of thyroid hormones in
mood disorder offers promising insights into the thyroid–brain
relationship.
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Figure 3. Brain areas where change in relative activity after treatment was correlated with change in depressed mood (Hamilton Rating Scale
for Depression (HamD17)). Colors superimposed on a gray-scale structural magnetic resonance template indicate areas from whole-brain
analysis of patients with bipolar disorder where change in relative metabolism from before to after treatment was directly correlated (t≥ 1.69;
Po0.05) with change in HamD17 scores in the levothyroxine (L-T4 group; top row), placebo group (center row), or where the correlation was
greater in L-T4 than placebo-treated patients (bottom row). Coordinates are in Montreal Neurological Institute (MNI) space depicted in
neurological orientation. There were no areas where change in activity was inversely correlated with change in HamD17 scores. PLA, placebo.
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